Bridgefront Capital’s Ascendis Pharma A/S ASND Stock Holding History

Bridgefront Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,442	Closed	-$330K	–	511
2026 Q1	$330K	Buy	+1,442	New	+$323K	0.08%	368
2025 Q2	–	Sell	-1,714	Closed	-$267K	–	603
2025 Q1	$267K	Buy	+1,714	New	+$245K	0.08%	429
2022 Q1	–	Sell	-1,708	Closed	-$230K	–	268
2021 Q4	$230K	Buy	1,708 +416	+32%	+$61.9K	0.22%	202
2021 Q3	$206K	Buy	+1,292	New	+$177K	0.21%	239

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Bridgefront Capital's ASND Position: Q2 2026 in Review

Bridgefront Capital sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 1,442 shares — an estimated $330K sold.

Bridgefront Capital first reported a position in ASND in Q3 2021 and held it in 4 quarters. The position peaked at $330K in Q1 2026. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Bridgefront Capital reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
Bridgefront Capital sold 1,442 Ascendis Pharma A/S shares in Q2 2026, an estimated $330K.
Bridgefront Capital first reported a position in Ascendis Pharma A/S in Q3 2021 and held it in 4 quarters.
Bridgefront Capital's Ascendis Pharma A/S position peaked at $330K in Q1 2026.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.